| 摘要 |
A therapeutic process for treating an inflammatory bowel disease (IBD) using mesenchymal stem cells includes the steps of isolating a plurality of human mesenchymal stem cells from a human patient, introducing the plurality of human mesenchymal stem cells into the human patient, reducing human pro-inflammatory cytokines, wherein the human pro-inflammatory cytokines include IL-12 and IL-18, and increasing human anti-inflammatory cytokines, wherein the human anti-inflammatory cytokines include IL-10 and TGF-beta. The human mesenchymal stem cells are isolated from an umbilical cord blood or from a human adipose tissue. The plurality of human mesenchymal stem cells is introduced into the human patient through a intravenous administration or through an enema. The plurality of human mesenchymal stem cells is reconstituted into growth factor rich plasma prior to being introduced into the human patient. |
